Targeted treatments for breast cancer
Thursday 25 May 2017, Christie Hospital Manchester1-day course: Targeted Treatments for Breast Cancer
Level: Intermediate
Description: This study day will describe many different faulty processes that drive the growth and spread of breast cancer. It will also introduce the science behind a plethora of licensed and yet-to-be licensed breast cancer treatments such as HER2-targeted therapies, PARP inhibitors and CDK inhibitors. To set the scene, the science behind standard treatments such as chemotherapy, radiotherapy and hormone therapy will be explained.
Audience: Ideal for research nurses, clinical nurse specialists, administrative staff, clinical trials coordinators
To book, contact: education.events@christie.nhs.uk or call: 0161 446 3403
Programme:
Cancer cell biology & genetics – key concepts:
- Cells, DNA, chromosomes, genes, proteins
- Cell division & the cell cycle
- Causes, types and consequences of DNA damage
- Drivers of treatment resistance: the cancer microenvironment, genomic instability, intra-umoural heterogeneity
The cellular and molecular makeup of breast cancer
- How breast cancer develops
- Faulty genes and proteins that drive breast cancer
- The role of hormone receptors and HER2
- Breast cancer stem cells
- How and why breast cancers spread
The science behind cancer treatments
- The mechanism of action of chemotherapy and radiotherapy
- The history of hormone therapies for cancer
- Targeting cell communication pathways: monoclonal antibodies and kinase inhibitors
Targeted treatments for breast cancer
- The current landscape of breast cancer treatments
- Hormone therapies – targeting the oestrogen receptor and aromatase
- HER2-targeted treatments: trastuzumab, pertuzumab, lapatinib & T-DM1
- PI3K/AKT/mTOR pathway inhibitors e.g. everolimus , copanlisib, buparlisib
More targeted treatments for breast cancer
- BRCA genes & PARP inhibitors
- CDK inhibitors e.g. palbociclib
- New targets for triple-negative/basal-like breast cancer
- Immunotherapy for breast cancer